Compare Avient Corporation (AVNT) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Heron Therapeutics Inc — how do they compare? Avient Corporation trades at $35.83 (market cap $3.28B), while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Avient Corporation is far larger — about 39.7× Heron Therapeutics Inc's market cap, and Avient Corporation pays a 3.07% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AVNT | HRTX | |
|---|---|---|
Market Cap | $3.28B | $82.52M |
Sector | Technology | Health |
52-Week High | $43.28 | $2.04 |
52-Week Low | $27.48 | $0.39 |
Enterprise Value | $4.78B | $180.42M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.
AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
